Inogen Expects 2026 Revenue of $373 Million
For the full year 2026, Inogen expects reported revenue in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint of the range relative to the Company's 2025 revenue. The Company remains committed to driving positive Adjusted EBITDA improvement in 2026.
Trade with 70% Backtested Accuracy
Analyst Views on INGN
About INGN
About the author
Inogen Reports Q4 2025 Earnings with Strategic Growth Insights
- Revenue Growth: Inogen reported approximately $82 million in total revenue for Q4 2025, with nearly $349 million for the full year, reflecting a 4% year-over-year growth and successfully meeting its mid-single-digit growth target for 2025, indicating stable market performance.
- International Business Highlight: The international segment delivered $32.5 million in revenue for Q4, representing a 15% year-over-year increase, marking it as a bright spot in the company's results and underscoring the importance of international expansion for long-term growth.
- New Product Launch: The company initiated a limited market release of Simeox in the U.S. and is nearing completion of a clinical study in China, expected to support a commercial launch in the second half of the year, thereby enhancing its product portfolio and market competitiveness.
- Share Repurchase Program: The Board of Directors authorized a $30 million share repurchase program intended for execution over 2026 and 2027, aimed at enhancing shareholder value and reflecting management's confidence in the company's future growth prospects.
Inogen Set to Release Q4 Earnings on February 24
- Earnings Announcement: Inogen (INGN) is scheduled to announce its Q4 earnings on February 24 after market close, with market participants keenly awaiting the results, which could have a short-term impact on the stock price.
- Earnings Expectations: The consensus EPS estimate stands at -$0.18, reflecting a significant year-over-year improvement of 56.1%, indicating a potential enhancement in the company's profitability that may boost investor confidence.
- Revenue Forecast: The anticipated revenue for Q4 is $82 million, representing a modest year-over-year growth of 2.4%, which, while limited, demonstrates the company's stability in the market and may attract inflows from investors seeking reliable returns.
- Performance Consistency: Over the past year, Inogen has consistently beaten both EPS and revenue estimates 100% of the time, and this track record of exceeding expectations could further bolster market confidence in its future performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Therapy Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant milestone in its respiratory care portfolio, aimed at providing high-quality masks for patients with obstructive sleep apnea, thereby expanding market opportunities.
- Market Positioning: Designed for superior comfort and reliability, the Aurora masks enhance Inogen's competitiveness in the rapidly growing sleep therapy market, with plans to leverage existing distribution channels to strengthen relationships with healthcare providers.
- User Feedback: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, indicating strong market acceptance and potential for sales growth.
- Technical Advantages: Featuring high-quality headgear and medical-grade silicone cushions, the Aurora masks provide a comfortable fit and are universally compatible with most CPAP devices, meeting FDA 510(k) standards for safety and performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant advancement in its home respiratory solutions, aimed at addressing the needs of patients with obstructive sleep apnea, thereby broadening its market coverage.
- Market Opportunity: Designed for superior comfort and reliability, the Aurora masks are expected to enhance Inogen's competitiveness in the rapidly growing sleep therapy market, further increasing its market share.
- Customer Satisfaction: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, establishing a solid foundation for Inogen's market entry.
- Strategic Partnerships: Inogen plans to leverage its existing distribution channels and partnerships to bring the Aurora masks to market, strengthening relationships with healthcare providers and reinforcing its leadership position in home respiratory care.
Three MedTech Pioneers Transforming Healthcare by 2026: AVAH, INGN, and CCLD
Healthcare Innovation Focus: Investors are increasingly interested in companies that innovate healthcare delivery to reduce costs and improve quality, particularly in ambulatory and home care settings, amid rising healthcare expenses and workforce shortages.
Aveanna Healthcare Overview: Aveanna Healthcare is positioned for growth with a diverse service mix in home care, expecting significant revenue increases and operational momentum, despite potential risks from labor costs and reimbursement policies.
Inogen's Market Position: Inogen specializes in portable oxygen concentrators, showing signs of recovery and growth through innovation and cost discipline, making it a notable player in the respiratory care market for 2026.
CareCloud's Technological Advancements: CareCloud offers a comprehensive suite of healthcare IT solutions, focusing on AI-driven efficiencies to improve operational performance, with promising earnings growth projections and a strong market position.
Wall Street Analysts Predict 35.64% Growth Potential for Inogen (INGN): Is Such a Surge Possible?
Stock Performance and Price Targets: Inogen (INGN) shares have risen 25.2% recently, with Wall Street analysts suggesting a mean price target of $11, indicating a potential upside of 35.6%, despite some estimates predicting declines.
Analyst Insights and Earnings Revisions: Analysts show growing optimism for INGN's earnings, with a Zacks Rank #2 (Buy) reflecting strong agreement on positive earnings revisions, which historically correlate with stock price movements.
Inogen Reports Q4 2025 Earnings with Strategic Growth Insights
- Revenue Growth: Inogen reported approximately $82 million in total revenue for Q4 2025, with nearly $349 million for the full year, reflecting a 4% year-over-year growth and successfully meeting its mid-single-digit growth target for 2025, indicating stable market performance.
- International Business Highlight: The international segment delivered $32.5 million in revenue for Q4, representing a 15% year-over-year increase, marking it as a bright spot in the company's results and underscoring the importance of international expansion for long-term growth.
- New Product Launch: The company initiated a limited market release of Simeox in the U.S. and is nearing completion of a clinical study in China, expected to support a commercial launch in the second half of the year, thereby enhancing its product portfolio and market competitiveness.
- Share Repurchase Program: The Board of Directors authorized a $30 million share repurchase program intended for execution over 2026 and 2027, aimed at enhancing shareholder value and reflecting management's confidence in the company's future growth prospects.
Inogen Set to Release Q4 Earnings on February 24
- Earnings Announcement: Inogen (INGN) is scheduled to announce its Q4 earnings on February 24 after market close, with market participants keenly awaiting the results, which could have a short-term impact on the stock price.
- Earnings Expectations: The consensus EPS estimate stands at -$0.18, reflecting a significant year-over-year improvement of 56.1%, indicating a potential enhancement in the company's profitability that may boost investor confidence.
- Revenue Forecast: The anticipated revenue for Q4 is $82 million, representing a modest year-over-year growth of 2.4%, which, while limited, demonstrates the company's stability in the market and may attract inflows from investors seeking reliable returns.
- Performance Consistency: Over the past year, Inogen has consistently beaten both EPS and revenue estimates 100% of the time, and this track record of exceeding expectations could further bolster market confidence in its future performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Therapy Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant milestone in its respiratory care portfolio, aimed at providing high-quality masks for patients with obstructive sleep apnea, thereby expanding market opportunities.
- Market Positioning: Designed for superior comfort and reliability, the Aurora masks enhance Inogen's competitiveness in the rapidly growing sleep therapy market, with plans to leverage existing distribution channels to strengthen relationships with healthcare providers.
- User Feedback: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, indicating strong market acceptance and potential for sales growth.
- Technical Advantages: Featuring high-quality headgear and medical-grade silicone cushions, the Aurora masks provide a comfortable fit and are universally compatible with most CPAP devices, meeting FDA 510(k) standards for safety and performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant advancement in its home respiratory solutions, aimed at addressing the needs of patients with obstructive sleep apnea, thereby broadening its market coverage.
- Market Opportunity: Designed for superior comfort and reliability, the Aurora masks are expected to enhance Inogen's competitiveness in the rapidly growing sleep therapy market, further increasing its market share.
- Customer Satisfaction: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, establishing a solid foundation for Inogen's market entry.
- Strategic Partnerships: Inogen plans to leverage its existing distribution channels and partnerships to bring the Aurora masks to market, strengthening relationships with healthcare providers and reinforcing its leadership position in home respiratory care.
Three MedTech Pioneers Transforming Healthcare by 2026: AVAH, INGN, and CCLD
Healthcare Innovation Focus: Investors are increasingly interested in companies that innovate healthcare delivery to reduce costs and improve quality, particularly in ambulatory and home care settings, amid rising healthcare expenses and workforce shortages.
Aveanna Healthcare Overview: Aveanna Healthcare is positioned for growth with a diverse service mix in home care, expecting significant revenue increases and operational momentum, despite potential risks from labor costs and reimbursement policies.
Inogen's Market Position: Inogen specializes in portable oxygen concentrators, showing signs of recovery and growth through innovation and cost discipline, making it a notable player in the respiratory care market for 2026.
CareCloud's Technological Advancements: CareCloud offers a comprehensive suite of healthcare IT solutions, focusing on AI-driven efficiencies to improve operational performance, with promising earnings growth projections and a strong market position.
Wall Street Analysts Predict 35.64% Growth Potential for Inogen (INGN): Is Such a Surge Possible?
Stock Performance and Price Targets: Inogen (INGN) shares have risen 25.2% recently, with Wall Street analysts suggesting a mean price target of $11, indicating a potential upside of 35.6%, despite some estimates predicting declines.
Analyst Insights and Earnings Revisions: Analysts show growing optimism for INGN's earnings, with a Zacks Rank #2 (Buy) reflecting strong agreement on positive earnings revisions, which historically correlate with stock price movements.
